Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 01.02.2023
Eloro Resources Ltd.
Highest and most extensive silver grades intersected
Eloro Resources announced assay results from eight more diamond drill holes
from its drilling programme at the Iska Iska silver-tin polymetallic
project in the Potosi Department, South Bolivia. With consistent high
silver grades averaging 69.80g Ag/t over a length of 325.48m in drill hole [ … ]
Wed, 01.02.2023
Eloro Resources Ltd.
Highest and most extensive silver grades intersected
Eloro Resources announced assay results from eight more diamond drill holes
from its drilling programme at the Iska Iska silver-tin polymetallic
project in the Potosi Department, South Bolivia. With consistent high
silver grades averaging 69.80g Ag/t over a length of 325.48m in drill hole [ … ]
Wed, 25.01.2023
Spexis AG
First Berlin Equity Research has initiated coverage on Spexis AG (ISIN:
CH0106213793). Analyst Christian Orquera's rating is BUY with a price
target of CHF 1.80.
Abstract:
Spexis AG is a biotech company with a clinical-stage product pipeline
focused on rare diseases and oncology. Spexis is the result of the merger
of the rare diseases specialist [ … ]
Tue, 24.01.2023
Almonty Industries Inc.
Almonty with placement of AUD 2.0mn
Almonty Industries has received firm commitments for issuing 2.5mn Chess
Depository Interests (CDIs) at a price of AUD 0.80 per CDI for gross
proceeds to the Company of CAD 2.0mn. The commitment was indicated by
Australian institutional investors who requested to increase their stake in
Almonty. According [ … ]
Tue, 17.01.2023
MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG
(ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und senkt das Kursziel von EUR 58,00 auf EUR 56,00.
Zusammenfassung:
Das schlechte Marktumfeld verstärkte den Abwärtstrend, der den NAVPS von
MPH Ende Q3/22 auf ei [ … ]
Wed, 11.01.2023
Saturn Oil & Gas Inc.
First Berlin Equity Research has published a research update on Saturn Oil
& Gas Inc. (ISIN: CA80412L8832). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from CAD 7.00 to CAD 6.30.
Abstract:
The Viking acquisition (consolidated from 6 July 2022) was the main driver
of a 49.7% rise in Saturn's output to 10,965 [ … ]
Mon, 19.12.2022
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 38.00 to EUR 34.00.
Abstract:
In its preliminary Q3/22 results release on 14 October DRAG cautioned that
FY/22 production would likely come in at the lo [ … ]
Mon, 19.12.2022
Deutsche Rohstoff AG
First Berlin Equity Research has published a research update on Deutsche
Rohstoff AG (ISIN: DE000A0XYG76). Analyst Simon Scholes reiterated his BUY
rating and decreased the price target from EUR 38.00 to EUR 34.00.
Abstract:
In its preliminary Q3/22 results release on 14 October DRAG cautioned that
FY/22 production would likely come in at the lo [ … ]
Thu, 15.12.2022
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal stuft die
Aktie auf ADD herauf und erhöht das Kursziel von EUR 18,10 auf EUR 26,00.
Zusammenfassung:
Im November stellte PNE auf ihrem Kapitalmarkttag ihre Wachstumsstrategie
2023 - 2027 ('Scale up 2.0' [ … ]
Thu, 15.12.2022
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal stuft die
Aktie auf ADD herauf und erhöht das Kursziel von EUR 18,10 auf EUR 26,00.
Zusammenfassung:
Im November stellte PNE auf ihrem Kapitalmarkttag ihre Wachstumsstrategie
2023 - 2027 ('Scale up 2.0' [ … ]